Woebot Health
Clinically-grounded conversational mental health agent; consumer app retired 2025, now enterprise-only.
Retired
Woebot Health appears to be discontinued or shut down — The direct-to-consumer Woebot app shut down on June 30, 2025; Woebot Health continues as an enterprise-only platform for health systems, payers, and employers. This page is kept as an archive record and is excluded from search engines.
About
Woebot Health built one of the most studied mental health chatbots: a relational agent whose scripted conversations are written by clinical writers and psychologists using CBT, IPT, and DBT techniques. Its published research includes multiple randomized controlled trials and a study of over 36,000 users on therapeutic bond formation, and its WB001 digital therapeutic for postpartum depression received FDA Breakthrough Device designation in 2021. The company reports over 72 million minutes of mental health support delivered.
On June 30, 2025 Woebot Health shut down its direct-to-consumer app and pivoted to enterprise-only, licensing the platform to health systems, payers, and employers through EMR-integrated deployments. The company continues to operate with HIPAA compliance, SOC 2 Type 2 examination, and validated outcome scales like the PHQ-9, with 2026 reports of new payer contracts including Bayer.
What it can do
- CBT/IPT/DBT scripted conversations
- EMR-integrated deployments
- Validated PHQ-8/PHQ-9 outcome collection
- Crisis language detection and referral
- Population modules for adults, teens, maternal health, 65+
- HIPAA and SOC 2 Type 2 compliance
- FDA Breakthrough Device designation (WB001)
Setup
Enterprise licensing through health systems, payers, or employers; no consumer app available.
Prerequisites
Access through a participating health plan, employer, or health system.
Use cases
Works with
Trust score — 6/10
Scored 7/10 (TIER verified, metrics-v1). Evidence: multiple independent outlets confirm the June 30, 2025 consumer shutdown and the enterprise pivot; FDA Breakthrough Device designation for WB001 (2021) and RCT publications are documented; enterprise deployments with health systems confirmed via Business Wire. Strengths: strongest clinical evidence base of any consumer-originated mental health chatbot, audit-ready compliance posture. Docked for: (1) consumer product retired, no individual access; (2) most enterprise products are wellness adjuncts, not FDA cleared. License: proprietary.
How the trust score is built
Full methodology →- Adoption · stars/downloads, log-scaled vs peers
- 7.0/10
- Maintenance · recency, releases, issue load
- 6.0/10
- Openness · license + docs
- 5.0/10
- Manual review · sanity read + red-flag check
- 8.0/10
- · Consumer app retired 2025-06-30; company continues B2B for health systems, payers, employers
- · FDA Breakthrough Device designation for WB001 (2021); multiple published RCTs
- · Most enterprise products are wellness adjuncts, not FDA cleared
Sources
Every fact above was checked against these sources. Where a claim comes from the provider and couldn't be independently verified, the text says so.